Julia Hoellenriegel

2.3k total citations · 1 hit paper
18 papers, 1.4k citations indexed

About

Julia Hoellenriegel is a scholar working on Genetics, Molecular Biology and Immunology. According to data from OpenAlex, Julia Hoellenriegel has authored 18 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Genetics, 6 papers in Molecular Biology and 5 papers in Immunology. Recurrent topics in Julia Hoellenriegel's work include Chronic Lymphocytic Leukemia Research (16 papers), Immunodeficiency and Autoimmune Disorders (4 papers) and Glycosylation and Glycoproteins Research (3 papers). Julia Hoellenriegel is often cited by papers focused on Chronic Lymphocytic Leukemia Research (16 papers), Immunodeficiency and Autoimmune Disorders (4 papers) and Glycosylation and Glycoproteins Research (3 papers). Julia Hoellenriegel collaborates with scholars based in United States, Germany and Italy. Julia Hoellenriegel's co-authors include William G. Wierda, Michael J. Keating, Jan A. Burger, Hagop M. Kantarjian, Mariela Sivina, Susan O’Brien, Brian J. Lannutti, Sarah Meadows, Neill A. Giese and Langdon L. Miller and has published in prestigious journals such as Blood, PLoS ONE and The Lancet Oncology.

In The Last Decade

Julia Hoellenriegel

18 papers receiving 1.4k citations

Hit Papers

The phosphoinositide 3′-k... 2011 2026 2016 2021 2011 100 200 300 400
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. The phosphoinositide 3′-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia
    2011 442 citations Julia Hoellenriegel, Sarah Meadows et al. Blood profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Julia Hoellenriegel United States 10 900 656 466 421 305 18 1.4k
Nahla Farahat United Kingdom 16 490 0.5× 490 0.7× 294 0.6× 413 1.0× 427 1.4× 31 1.3k
Jun Takizawa Japan 18 263 0.3× 426 0.6× 191 0.4× 340 0.8× 207 0.7× 75 1.1k
Riccardo Dalla-Favera United States 8 673 0.7× 964 1.5× 642 1.4× 687 1.6× 167 0.5× 10 1.9k
Chrysoula Belessi Greece 23 1.1k 1.2× 800 1.2× 260 0.6× 753 1.8× 153 0.5× 57 1.4k
Michelle Francesco United States 12 444 0.5× 371 0.6× 259 0.6× 1.2k 2.9× 191 0.6× 16 1.9k
G Dighiero France 17 1.3k 1.4× 874 1.3× 545 1.2× 1.1k 2.5× 230 0.8× 40 2.0k
Tony G. Willis United Kingdom 13 553 0.6× 890 1.4× 675 1.4× 513 1.2× 186 0.6× 17 1.8k
T J Kipps United States 16 623 0.7× 429 0.7× 392 0.8× 700 1.7× 121 0.4× 23 1.4k
K Weber-Matthiesen Germany 19 341 0.4× 552 0.8× 258 0.6× 219 0.5× 214 0.7× 33 1.1k
Anna Migliazza Italy 19 862 1.0× 1.2k 1.8× 1.0k 2.2× 877 2.1× 121 0.4× 28 2.7k

Countries citing papers authored by Julia Hoellenriegel

Since Specialization
Citations

This map shows the geographic impact of Julia Hoellenriegel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Julia Hoellenriegel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Julia Hoellenriegel more than expected).

Fields of papers citing papers by Julia Hoellenriegel

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Julia Hoellenriegel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Julia Hoellenriegel. The network helps show where Julia Hoellenriegel may publish in the future.

Co-authorship network of co-authors of Julia Hoellenriegel

This figure shows the co-authorship network connecting the top 25 collaborators of Julia Hoellenriegel. A scholar is included among the top collaborators of Julia Hoellenriegel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Julia Hoellenriegel. Julia Hoellenriegel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
Landau, Dan A., Clare Sun, Daniel Rosebrock, et al.. (2016). The Landscape of Dynamic Genetic Changes in Ibrutinib-Treated CLL. Blood. 128(22). 188–188. 2 indexed citations
2.
Burger, Jan A., Michael J. Keating, William G. Wierda, et al.. (2014). Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study. The Lancet Oncology. 15(10). 1090–1099. 260 indexed citations
3.
Fiorcari, Stefania, Wells S. Brown, Bradley W. McIntyre, et al.. (2013). The PI3-Kinase Delta Inhibitor Idelalisib (GS-1101) Targets Integrin-Mediated Adhesion of Chronic Lymphocytic Leukemia (CLL) Cell to Endothelial and Marrow Stromal Cells. PLoS ONE. 8(12). e83830–e83830. 75 indexed citations
4.
Hoellenriegel, Julia, Elena Hartmann, Andreas Rosenwald, et al.. (2013). Longitudinal Gene Expression Profiling Reveals Down-Regulation Of BCR Signaling-Related Genes In Chronic Lymphocytic Leukemia (CLL) Patients Treated With Ibrutinib Plus Rituximab. Blood. 122(21). 1631–1631. 1 indexed citations
5.
Burger, Jan A., Dan A. Landau, Julia Hoellenriegel, et al.. (2013). Clonal Evolution In Patients With Chronic Lymphocytic Leukemia (CLL) Developing Resistance To BTK Inhibition. Blood. 122(21). 866–866. 22 indexed citations
6.
Hoellenriegel, Julia, Dirk Zboralski, Christian Maasch, et al.. (2013). The Spiegelmer NOX-A12, a novel CXCL12 inhibitor, interferes with chronic lymphocytic leukemia cell motility and causes chemosensitization. Blood. 123(7). 1032–1039. 179 indexed citations
7.
8.
Hoellenriegel, Julia, Greg Coffey, Uma Sinha, et al.. (2012). Selective, novel spleen tyrosine kinase (Syk) inhibitors suppress chronic lymphocytic leukemia B-cell activation and migration. Leukemia. 26(7). 1576–1583. 114 indexed citations
9.
Burger, Jan A., Michael J. Keating, William G. Wierda, et al.. (2012). The Btk Inhibitor Ibrutinib (PCI-32765) in Combination with Rituximab Is Well Tolerated and Displays Profound Activity in High-Risk Chronic Lymphocytic Leukemia (CLL) Patients. Blood. 120(21). 187–187. 42 indexed citations
10.
Zboralski, Dirk, Julia Hoellenriegel, Christian Maasch, Anna Kruschinski, & Jan A. Burger. (2012). Mode of Action of the SDF-1/CXCL12 Inhibiting Spiegelmer® Nox-A12 and Its Impact On Chronic Lymphocytic Leukemia (CLL) Cell Motility and Chemosensitization. Blood. 120(21). 318–318. 2 indexed citations
11.
Hoellenriegel, Julia, Susan O’Brien, Michael J. Keating, et al.. (2012). In Vivo Inhibition of BCR Activation in High-Risk CLL Patients On Therapy with Bruton's Tyrosine Kinase Inhibitor Ibrutinib: Correlative Studies from an Ongoing Phase 2 Clinical Trial. Blood. 120(21). 186–186. 4 indexed citations
12.
Hoellenriegel, Julia, Sarah Meadows, Mariela Sivina, et al.. (2011). The phosphoinositide 3′-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia. Blood. 118(13). 3603–3612. 442 indexed citations breakdown →
13.
Fiorcari, Stefania, Wells S. Brown, Bradley W. McIntyre, et al.. (2011). The PI3 Kinase δ Inhibitor, CAL-101 (GS-1101), Inhibits Chronic Lymphocytic Leukemia (CLL) Cell Survival in Endothelial and Marrow Stromal Cell Co-Cultures.. Blood. 118(21). 1769–1769. 2 indexed citations
14.
Hoellenriegel, Julia, Dirk Zboralski, Zeev Estrov, et al.. (2011). The Spiegelmer Nox-A12, a Novel SDF-1 (CXCL12) Inhibitor, and Its Effects on Chronic Lymphocytic Leukemia (CLL) Cell Migration,. Blood. 118(21). 3878–3878. 3 indexed citations
15.
16.
Hoellenriegel, Julia, Greg Coffey, Uma Sinha, et al.. (2010). Spleen Tyrosine Kinase (Syk) Inhibitors Block B Cell Receptor Signaling and Survival In Chronic Lymphocytic Leukemia. Blood. 116(21). 3604–3604. 1 indexed citations
17.
Schwarz, Alexandra, Michael Foss, Lixin Zhou, et al.. (2010). Nucleoporin 153 Arrests the Nuclear Import of Hepatitis B Virus Capsids in the Nuclear Basket. PLoS Pathogens. 6(1). e1000741–e1000741. 125 indexed citations
18.
Janßen, Andreas, Julia Hoellenriegel, Heinrich Schrewe, et al.. (2008). Abnormal Vessel Formation in the Choroid of Mice Lacking Tissue Inhibitor of Metalloprotease-3. Investigative Ophthalmology & Visual Science. 49(7). 2812–2812. 56 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Nahla Farahat Breakdown of academic impact, for papers by Jun Takizawa Breakdown of academic impact, for papers by Riccardo Dalla-Favera Breakdown of academic impact, for papers by Chrysoula Belessi Breakdown of academic impact, for papers by Michelle Francesco Breakdown of academic impact, for papers by G Dighiero Breakdown of academic impact, for papers by Tony G. Willis Breakdown of academic impact, for papers by T J Kipps Breakdown of academic impact, for papers by K Weber-Matthiesen Breakdown of academic impact, for papers by Anna Migliazza
Rankless by CCL
2026